Nuon Therapeutics, Inc., located in the San Francisco Bay Area, is focused on the development and commercialization of new therapies for autoimmune and rheumatic disease, including chronic gout and rheumatoid arthritis (RA), and other autoimmune diseases.
The company acquires and develops drugs for the treatment of unmet medical needs through discovering new uses for existing drugs that have established safety records.
Nuon Therapeutics, Inc., a privately held, clinical stage, biopharmaceutical company, was founded in 2006. In June 2007, the Company raised a U.S. $5 millon Series ‘A’ round of equity funding from GBS Ventures. The Company became a Delaware Corporation in July 2007 with corporate headquarters located in San Mateo, California. In March 2008, Nuon raised a U.S. $33 million Series ‘B’ round of equity funding led by Domain Associates and Frazier Healthcare Ventures, joined by GBS Ventures.
Nuon Therapeutics, Inc. has assembled a management team with proven experience in developing and commercializing medicines for patients with unmet medical needs. Nuon’s scientific founders, who are involved in the scientific guidance of the company, have demonstrated success in translating scientific advances into practical therapeutics for the treatment of autoimmune and rheumatic diseases.